Literature DB >> 21279353

Assessment of the treatment response of HCC.

Kyung Won Kim1, Jeong Min Lee, Byung Ihn Choi.   

Abstract

Surgical hepatectomy or liver transplantation are considered as curative treatment modalities for hepatocellular carcinoma (HCC). However, many patients are not surgical candidates at the time of diagnosis. Great improvements in locoregional therapies including local ablative therapy [radiofrequency (RF) ablation or ethanol ablation] and transarterial techniques (transarterial embolization or transarterial radioembolization) have made possible local control of HCC. For unresectable HCC, a targeted therapy with sorafenib may improve survival. Unlike treatment of other oncologic tumor, the locoregional therapies are mainstay in the treatment of HCC. Therefore, the application of classical criteria such as the World Health Organization (WHO) guideline may not be suitable for accurate treatment response assessment of locoregional therapies or targeted therapy of HCC. An understanding of the imaging features of post-treatment imaging after various treatment modalities for HCC is crucial for treatment response assessment and for determining further therapy. In this article, we review the role of various imaging modalities in assessing treatment response of locoregional therapies and the targeted molecular therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21279353     DOI: 10.1007/s00261-011-9683-3

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  17 in total

Review 1.  Cancer of unknown primary sites: what radiologists need to know and what oncologists want to know.

Authors:  Kyung Won Kim; Katherine M Krajewski; Jyothi P Jagannathan; Mizuki Nishino; Atul B Shinagare; Jason L Hornick; Nikhil H Ramaiya
Journal:  AJR Am J Roentgenol       Date:  2013-03       Impact factor: 3.959

Review 2.  Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging.

Authors:  Kyung Won Kim; Katherine M Krajewski; Mizuki Nishino; Jyothi P Jagannathan; Atul B Shinagare; Sree Harsha Tirumani; Nikhil H Ramaiya
Journal:  AJR Am J Roentgenol       Date:  2013-10       Impact factor: 3.959

3.  Usefulness of F-18 FDG PET/CT in the Evaluation of Early Treatment Response After Interventional Therapy for Hepatocellular Carcinoma.

Authors:  Sung Hoon Kim; Kyoung Sook Won; Byung Wook Choi; Il Jo; Seok Kil Zeon; Woo Jin Chung; Jung Hyeok Kwon
Journal:  Nucl Med Mol Imaging       Date:  2012-04-28

Review 4.  MRI Assessment of Hepatocellular Carcinoma after Local-Regional Therapy: A Comprehensive Review.

Authors:  Mishal Mendiratta-Lala; William R Masch; Kimberly Shampain; Andrew Zhang; Alexandria S Jo; Sarah Moorman; Anum Aslam; Katherine E Maturen; Matthew S Davenport
Journal:  Radiol Imaging Cancer       Date:  2020-01-31

5.  Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.

Authors:  Giuseppe Salvaggio; Alessandro Furlan; Francesco Agnello; Giuseppe Cabibbo; Daniele Marin; Lydia Giannitrapani; Chiara Genco; Massimo Midiri; Roberto Lagalla; Giuseppe Brancatelli
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

6.  Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.

Authors:  Marco Baron Toaldo; Veronica Salvatore; Sara Marinelli; Chiara Palamà; Maddalena Milazzo; Luca Croci; Laura Venerandi; Mario Cipone; Luigi Bolondi; Fabio Piscaglia
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

7.  [Diagnosis of and therapy for hepatocellular carcinoma].

Authors:  T F Greten; N P Malek; S Schmidt; J Arends; P Bartenstein; W Bechstein; T Bernatik; M Bitzer; A Chavan; M Dollinger; D Domagk; O Drognitz; M Düx; S Farkas; G Folprecht; P Galle; M Geißler; G Gerken; D Habermehl; T Helmberger; K Herfarth; R T Hoffmann; M Holtmann; P Huppert; T Jakobs; M Keller; J Klempnauer; F Kolligs; J Körber; H Lang; F Lehner; F Lordick; A Lubienski; M P Manns; A Mahnken; M Möhler; C Mönch; P Neuhaus; C Niederau; M Ocker; G Otto; P Pereira; G Pott; J Riemer; K Ringe; U Ritterbusch; E Rummeny; P Schirmacher; H J Schlitt; K Schlottmann; V Schmitz; A Schuler; H Schulze-Bergkamen; D von Schweinitz; D Seehofer; H Sitter; C P Straßburg; C Stroszczynski; D Strobel; A Tannapfel; J Trojan; I van Thiel; A Vogel; F Wacker; H Wedemeyer; H Wege; A Weinmann; C Wittekind; B Wörmann; C J Zech
Journal:  Z Gastroenterol       Date:  2013-11-15       Impact factor: 2.000

Review 8.  Computed Tomography and Ultrasounds for the Follow-up of Hepatocellular Carcinoma Ablation: What You Need to Know.

Authors:  Alexios Kelekis; Dimitrios Filippiadis
Journal:  Diagnostics (Basel)       Date:  2016-02-04

Review 9.  LI-RADS treatment response lexicon: review, refresh and resolve with emerging data.

Authors:  Roopa Ram; Rony Kampalath; Anuradha S Shenoy-Bhangle; Sandeep Arora; Ania Z Kielar; Mishal Mendiratta-Lala
Journal:  Abdom Radiol (NY)       Date:  2021-06-09

10.  Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolization.

Authors:  Mohamed E Salem; Nitin Jain; Gregory Dyson; Stephanie Taylor; Sherif M El-Refai; Minsig Choi; Anthony F Shields; Jeffery Critchfield; Philip A Philip
Journal:  ISRN Oncol       Date:  2013-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.